Controlled Directional Drug Release from Poly(ε-Caprolactone)/polyethylene Oxide/metoprolol Tartrate Composites with Multi-Layered Structures

Rui Pan
DOI: https://doi.org/10.1016/j.compositesa.2022.106939
IF: 9.463
2022-01-01
Composites Part A Applied Science and Manufacturing
Abstract:Multi-layered structure design has provided a promising and powerful strategy for the fabrication of controlled-release dosage forms. However, a convenient and effective preparation technology is still urgently needed. Herein, we applied layer-multiplying co-extrusion (LMCE) technology to construct poly(epsilon-caprolactone)-poly (epsilon-caprolactone)/polyethylene oxide/metoprolol tartrate (PCL-PCL/PEO/MPT) composites with alternating multi-layered structures in one step. The layer number could be doubled by an addition of layer-multiplying element. The degradation analysis indicated that fewer PCL layers were beneficial to the dissolution of PEO and increased the pore size in the matrix. The in vitro release results suggested the MPT encapsulated in PEO aggregates was released gradually in a layer-by-layer manner, and the MPT release was flexibly modulated by the number of PCL layer and PEO content. Additionally, methyl thiazolyl tetrazolium assay presented a potential application of PCL-PCL/PEO/MPT composites in tissue engineering. The LMCE technology should have great potential for the preparation of controlled-release dosage forms.
What problem does this paper attempt to address?